Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
O. Garrone
Observed names:
Garrone O,
Ornelia Garrone,
Ornella Garrone
Institution:
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Observed institutions:
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
ORCID:
0000-0001-7359-5410
Observed ORCID:
0000-0001-7359-5410
OpenAlex ID:
A5002166114
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.
2023
·
Pier Franco Conte
, Giancarlo Bisagni
, et al.
·
Journal of Clinical Oncology
·
9
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
2023
·
B. Trevisan
, F. F. Pepe
, et al.
·
Scientific Reports
·
6
PDF
Therapeutic vaccines targeting HPV epitopes in human papillomavirus – positive oropharyngeal cancer: a critical review
2026
·
Giovanna Rossi
, Francesco Carlo Tartaglia
, et al.
·
Frontiers in Immunology
·
5
PDF
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
2017
·
P. Conte
, P. Conte
, et al.
·
Annals of Oncology
·
5
134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
2022
·
L. Del Mastro
, F. Poggio
, et al.
·
Annals of Oncology
·
4
Prognostic Significance of MSI and EBV Positivity in PD ‐ L1 Positive Gastric Cancer: A Systematic Review and Meta‐Analysis
2026
·
Fausto Petrelli
, Maria Antista
, et al.
·
Cancer Medicine
·
3
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study
2026
·
M.E. Cazzaniga
, V. Cogliati
, et al.
·
ESMO Real World Data and Digital Oncology
·
2
PDF
Abstract PS4-12-24: Risk and Pattern of Relapse in Triple-Negative Breast Cancer with Pathological Complete Response after Neoadjuvant Treatment: Updated Results from the European GAMBIT Real-world Study
2026
·
M. Dieci
, T. Foukakis
, et al.
·
Clinical Cancer Research
·
1
Abstract PS2-08-11: Artificial Intelligence (AI)-based spatial assessment of tumor-infiltrating lymphocytes (TIL) and outcome in early HER2+ breast cancer (BC): ancillary study of the phase III adjuvant ShortHER trial
2026
·
M. Dieci
, K. AbdulJabbar
, et al.
·
Clinical Cancer Research
·
1
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial
2025
·
M.V. Dieci
, G. Bisagni
, et al.
·
ESMO Open
·
1
390P Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): A multicentric, cohort study (DeReal-REST)
2025
·
A. Fabi
, A. Palazzo
, et al.
·
ESMO Open
·
1
PDF
394P CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
2023
·
F. Pantano
, R. Scafetta
, et al.
·
Annals of Oncology
·
1
PDF
70P Modulation of the prognostic role of stromal tumor-infiltrating-lymphocytes by tumor proliferation in triple-negative breast cancer: Results from the European GAMBIT network
2026
·
M.V. Dieci
, D. Massa
, et al.
·
ESMO Open
Abstract PS3-09-18: Early AB-ITALY: Evaluating Real-World Use of Adjuvant Abemaciclib and Drug Interaction Risk in HR+/HER2- early Breast Cancer
2026
·
S. Scagnoli
, M. Verrico
, et al.
·
Clinical Cancer Research
Abstract PS1-10-29: Complete tumor response during first-line endocrine therapy (ET) plus Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i) predicts excellent clinical outcomes in patients with Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative advanced Breast Cancer (HR+/HER2- aBC)
2026
·
C. Vernieri
, R. Caputo
, et al.
·
Clinical Cancer Research
Abstract PS3-04-29: Machine Learning predicts early tumor progression in Hormone Receptor-positive, Human Epidermal growth factor Receptor 2-negative (HR+/HER2-) advanced breast cancer (aBC) patients treated with first-line endocrine therapy (ET) plus Cyclin Dependent Kinase 4/6 inhibitors (CDK4/6i)
2026
·
L. Provenzano
, R. Caputo
, et al.
·
Clinical Cancer Research
333P The role of denosumab in BRCA-mutated HR+/HER2- metastatic breast cancer with bone metastases: A multicenter retrospective study
2025
·
R. Scafetta
, M. Donato
, et al.
·
ESMO Open
199P Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: An exploratory analysis of the GIM2 trial
2025
·
C. De Angelis
, A. Rosa
, et al.
·
ESMO Open
11P Interaction between TILs and body mass index in early HER2+ BC patients: Analysis of the ShortHER trial
2025
·
M.V. Dieci
, G. Bisagni
, et al.
·
ESMO Open
PDF
Efficacy and Safety of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico Del Nord Ovest) Study
2021
·
Garrone O
, Giarratano T
, et al.
·
Clinics of Oncology
The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
2016
·
C. Fontanella
, L. Del Mastro
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
22
Citation count:
40
H-index:
4
I10-index:
Year
Topic
Type